US Patent

US8617597 — Pharmaceutical composition containing a tetrahydrofolic acid

Formulation · Assigned to Bayer Intellectual Property GmbH · Expires 2030-02-08 · 4y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a solid oral contraceptive composition containing drospirenone, ethinylestradiol, and calcium 5-methyl-(6S)-tetrahydrofolate.

USPTO Abstract

The present invention relates to solid pharmaceutical compositions, in particular to oral contraceptives, comprising a progestogen, such as drospirenone; an estrogen, such as ethinylestradiol; a tetrahydrofolic acid or a pharmaceutically acceptable salt thereof, such as calcium 5-methyl-(6S)-tetrahydrofolate; and at least one pharmaceutical acceptable excipient or carrier. The compositions of the invention provide good stability of the tetrahydrofolic acid upon storage while still ensuring a fast and reliable release of the estrogen and the progestogen present in the composition.

Drugs covered by this patent

Patent Metadata

Patent number
US8617597
Jurisdiction
US
Classification
Formulation
Expires
2030-02-08
Drug substance claim
No
Drug product claim
Yes
Assignee
Bayer Intellectual Property GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.